Home › Companies › REPL

Replimune Group

REPL Lead: NDA Submitted ★ Read the deep dive → 5 Biotech Distilled articles ↓

Oncology Gene Therapy

Most recent annual filing: 2026-06-29

Pipeline (5 active programs)

vusolimogene oderparepvec

RP1

Gene Therapy

Melanoma NDA Submitted intratumoral BMS
Cutaneous Squamous Cell Carcinoma Phase 2 intratumoral Bristol Myers Squibb

sturlimgene erparepvec

RP2

Gene Therapy Target: CTLA-4

Uveal Melanoma Phase 2 intratumoral Bristol Myers Squibb
Hepatocellular Carcinoma Phase 2 intratumoral Roche
Biliary Tract Cancer Phase 2 intratumoral

Technology platforms

RPx

Proprietary oncolytic immunotherapy platform based on an engineered HSV-1 backbone with multiple immune-activating payloads (GALV-GP R(-), GM-CSF, anti-CTLA-4, CD40L, 4-1BBL); designed for intratumoral administration to induce local and systemic anti-tumor immunity; focus areas: skin cancers, liver cancers, uveal melanoma, and other solid tumors

Discontinued (1)

RP3 — undisclosed · program deprioritized; not pursuing further development at this time

Biotech Distilled coverage (5)

2026-06-26 UPDATE: Replimune (REPL) - The Clock Is Set
2026-06-02 UPDATE: Replimune (REPL) - ASCO Delivers the Backstop 🔒 Paid
2026-05-29 UPDATE: Replimune (REPL) - The FDA Blinks
2026-04-10 UPDATE: Replimune (REPL) - The Hammer Drops 🔒 Paid
2026-02-17 Replimune (REPL): Scientific Deep Dive for RP1, RP2, and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.